MedTrace Logo

Bioequivalence Study Between YHP2205 and YHR2401 in Healthy Volunteers

NCT06359626 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-11-12

No results posted yet for this study

Summary

A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP2205 and YHR2401 in healthy volunteers

Conditions

  • Healthy Volunteers

Interventions

DRUG

YHP2205

Test drug: YHP2205

DRUG

YHR2401

comparator: YHR2401

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • Taegon Hong · Bumin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-21
Primary Completion
2024-06-30
Completion
2024-07-06

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06359626 on ClinicalTrials.gov